Oudin Claire, Auquier Pascal, Bertrand Yves, Chastagner Philippe, Kanold Justyna, Poirée Maryline, Thouvenin Sandrine, Ducassou Stephane, Plantaz Dominique, Tabone Marie-Dominique, Dalle Jean-Hugues, Gandemer Virginie, Lutz Patrick, Sirvent Anne, Villes Virginie, Barlogis Vincent, Baruchel André, Leverger Guy, Berbis Julie, Michel Gérard
Department of Pediatric Hematology and Oncology, Timone Enfants Hospital and Aix-Marseille University, France Research Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital Marseille, France
Research Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital Marseille, France.
Haematologica. 2016 Jun;101(6):747-56. doi: 10.3324/haematol.2015.140053. Epub 2016 Mar 11.
Thyroid complications are known side effects of irradiation. However, the risk of such complications in childhood acute leukemia survivors who received either central nervous system irradiation or hematopoietic stem cell transplantation is less described. We prospectively evaluated the incidence and risk factors for thyroid dysfunction and tumors in survivors of childhood acute myeloid or lymphoid leukemia. A total of 588 patients were evaluated for thyroid function, and 502 individuals were assessed for thyroid tumors (median follow-up duration: 12.6 and 12.5 years, respectively). The cumulative incidence of hypothyroidism was 17.3% (95% CI: 14.1-21.1) and 24.6% (95% CI: 20.4-29.6) at 10 and 20 years from leukemia diagnosis, respectively. Patients who received total body irradiation (with or without prior central nervous system irradiation) were at higher risk of hypothyroidism (adjusted HR: 2.87; P=0.04 and 2.79, P=0.01, respectively) as compared with transplanted patients who never received any irradiation. Patients transplanted without total body irradiation who received central nervous system irradiation were also at higher risk (adjusted HR: 3.39; P=0.02). Patients irradiated or transplanted at older than 10 years of age had a lower risk (adjusted HR: 0.61; P=0.02). Thyroid malignancy was found in 26 patients (5.2%). Among them, two patients had never received any type of irradiation: alkylating agents could also promote thyroid cancer. The cumulative incidence of thyroid malignancy was 9.6% (95% CI: 6.0-15.0) at 20 years. Women were at higher risk than men (adjusted HR: 4.74; P=0.002). In conclusion, thyroid complications are frequent among patients who undergo transplantation after total body irradiation and those who received prior central nervous system irradiation. Close monitoring is thus warranted for these patients. Clinicaltrials.gov identifier: NCT 01756599.
甲状腺并发症是已知的放疗副作用。然而,对于接受中枢神经系统放疗或造血干细胞移植的儿童急性白血病幸存者,此类并发症的风险描述较少。我们前瞻性评估了儿童急性髓系或淋巴细胞白血病幸存者甲状腺功能障碍和肿瘤的发生率及危险因素。共对588例患者进行了甲状腺功能评估,对502例个体进行了甲状腺肿瘤评估(中位随访时间分别为12.6年和12.5年)。从白血病诊断起10年和20年时,甲状腺功能减退的累积发生率分别为17.3%(95%CI:14.1 - 21.1)和24.6%(95%CI:20.4 - 29.6)。与从未接受任何放疗的移植患者相比,接受全身放疗(无论是否有中枢神经系统放疗史)的患者发生甲状腺功能减退的风险更高(校正后HR:2.87;P = 0.04和2.79,P = 0.01)。未接受全身放疗但接受中枢神经系统放疗的移植患者风险也更高(校正后HR:3.39;P = 0.02)。10岁以上接受放疗或移植的患者风险较低(校正后HR:0.61;P = 0.02)。发现26例患者(5.2%)患有甲状腺恶性肿瘤。其中,2例患者从未接受过任何类型的放疗:烷化剂也可促进甲状腺癌。20年时甲状腺恶性肿瘤的累积发生率为9.6%(95%CI:6.0 - 15.0)。女性风险高于男性(校正后HR:4.74;P = 0.002)。总之,在接受全身放疗后进行移植的患者以及既往接受中枢神经系统放疗的患者中,甲状腺并发症很常见。因此,有必要对这些患者进行密切监测。Clinicaltrials.gov标识符:NCT 01756599。